Kornimate/medical-research-clean huggingface dataset:
the efficacy of glucagon like peptide (glp) - 1(7-36) amide for glycemic control in critically ill patients

Conditions: Critically Ill; Hypoglycemia

Summary: the goal of this present proposal is to examine the efficacy of glp-1 administered to control blood glucose in critically ill patients.

all patients whom on admission to the icu (surgical, burn, \& cardiac) who are expected to receive intensive insulin therapy for at least 72 hours are eligible to be enrolled. once enrolled, the patients will be randomized to one of two groups: the experimental (intravenous glp-1 infusion for 72 hours) or control groups (intravenous 0.9% sodium chloride (nacl) infusion for 72 hours) in a double masked fashion. while enrolled, all patients will receive standard-of-care insulin therapy. both groups will be maintained on the standard icu specific protocol for glucose control.

Eligibility criteria:
inclusion criteria: * men and women age \> 21 to 75 years of age. * all subjects who meet icu specific criteria for inclusion in their glucose protocol and placed on insulin infusion protocol as standard of care. * able to obtain patient or proxy consent. exclusion criteria: * current diagnosis of malignancy. * type 1 diabetes. * inability to obtain informed consent. * on any phase 1 trial.

Keywords: intensive insulin therapy (iit) insulin infusion tight glycemic control intensive care units
perfusion magnetic resonance imaging in measuring the growth of blood vessels in newly diagnosed brain tumors

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: perfusion magnetic resonance imaging may be an effective method of measuring the growth of blood vessels in brain tumors. these measurements may help doctors better diagnose and treat brain tumors. purpose: pilot study to determine the effectiveness of perfusion magnetic resonance imaging in measuring the growth of blood vessels in newly diagnosed brain tumors.

objectives: i. correlate the findings of perfusion magnetic resonance imaging with known tissue and serum markers of angiogenesis in patients with newly diagnosed surgically resectable brain tumors. outline: patients undergo perfusion magnetic resonance imaging (mri) scanning with contrast in conjunction with preoperative conventional mri scanning with contrast. patients receive gadopentetate dimeglumine iv over 5 seconds prior to perfusion mri. gadopentetate dimeglumine is administered at a slower rate prior to conventional mri. patients undergo blood draw to determine urokinase type plasminogen activator levels. after completion of perfusion and conventional mri scanning, brain tumor tissue samples are obtained during surgical resection to determine tumor grade and type and urokinase type plasminogen activator and basic fibroblast growth factor levels. if csf removal is required during surgery, then csf samples are collected to determine urokinase type plasminogen activator and basic fibroblast growth factor levels. projected accrual: a total of 10 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: newly diagnosed surgically resectable brain tumor patient characteristics: age: over 18 performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: able to tolerate gadopentetate dimeglumine contrast medically stable prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: not specified radiotherapy: no prior radiotherapy surgery: see disease characteristics

Keywords: adult brain stem glioma adult ependymoma adult craniopharyngioma adult medulloblastoma adult meningioma adult glioblastoma adult oligodendroglioma adult anaplastic astrocytoma adult myxopapillary ependymoma adult anaplastic ependymoma adult anaplastic oligodendroglioma adult mixed glioma adult pineal parenchymal tumor adult central nervous system germ cell tumor adult pilocytic astrocytoma adult subependymoma adult diffuse astrocytoma adult ependymoblastoma adult pineocytoma adult pineoblastoma adult meningeal hemangiopericytoma adult choroid plexus tumor adult grade iii meningioma adult giant cell glioblastoma adult gliosarcoma
a phase 2 study to evaluate the efficacy and safety of tnx-102 sl in patients with multi-site pain associated with post-acute sequelae of sars-cov-2 infection

Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection; COVID-19; Long COVID; Long Haul COVID

Summary: this is a phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of tnx-102 sl 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management of multi-site pain associated with long covid.


Eligibility criteria:
major inclusion criteria: * the patient is male or female, 18 to 65 years of age, inclusive. * the patient has a polymerase chain reaction (pcr) confirmed history of sars-cov-2 infection at least 3 months prior to enrollment, based on a documented written positive viral test at the time of active infection. * the patient has new onset or significant worsening of pain that coincides with a prior covid-19 infection and has symptoms that have been generally present for at least 3 months but no longer than 18 months. major exclusion criteria: * the patient has been diagnosed with infectious or inflammatory arthritis (eg, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attack within past 2 years is exclusionary), or meets criteria for another type of systemic autoimmune disease (eg, sjogren's disease). * the patient has been diagnosed with a complex regional pain syndrome, fibromyalgia, failed back surgery syndrome, persistent or prevalent pain symptoms related to systemic disease (eg, diabetic peripheral neuropathy, post-herpetic neuropathy), untreated hyperparathyroidism, or a history of prior surgery, trauma, organ or tissue damage, or other source of pain that, in the investigator's opinion, would confound or interfere with the assessment of the patient's symptoms or require excluded therapies during the patient's study participation.

Keywords: multi-site pain sleep disturbance pasc covid-19 long covid coronavirus infections
effect of transcutaneous vagal nerve stimulation on reducing visually induced motion sickness in healthy volunteers

Conditions: Visually Induced Motion Sickness in Healthy Volunteers

Summary: nausea is a common and distressing experience that often precedes vomiting. amongst symptoms emanating from the gastrointestinal (gi) tract nausea can be considered somewhat unique, as on one hand it represents a normal, highly conserved, physiological response to an ingested toxin yet on the other it may indicate pathology. nausea may also arise as a consequence of pharmaco- and chemotherapeutic interventions. nausea negatively impacts on quality of life, adherence to treatment and is a cause for discontinuation of the development of novel compounds. experimentally, nausea can be induced in humans using a visually induced motion stimulus. previously we have developed a 10-minute motion video of the landscape rotating as seen from the perspective of a subject standing on westminster bridge, london. the tilted and rotating view visual display makes the subject perceive that they are spinning round and round on a spot tilted away from centre of gravity due to circular vection. this motion video induced nausea in approximately 50% of healthy participants and caused a reduction in cardiac vagal tone, a validated measure of the parasympathetic nervous system branch on the autonomic nervous system. we therefore are evaluating the role of external transcutaneous vagal nerve stimulation in visually induced motion sickness.


Eligibility criteria:
inclusion criteria: 1. healthy subjects, aged 18-65, from staff, students and local population of queen mary, university of london. 2. inclusion will be determined on the basis of availability, with no prior selection bias included. they should be able to attend the wingate institute for at least 2 x 1 hour sessions. 3. subjects who score \>15 on mssq (suggesting that they are sensitive to visually induced nausea). exclusion criteria: 1. subjects unable to provide informed consent. 2. subjects with any systemic disease or medications that may influence the autonomic nervous system (e.g. beta-agonists or parkinson's disease). 3. subjects who score \<15 on mssq (suggesting that they are insensitive to visually induced nausea). 4. pregnant females to prevent any confounding effects on pregnancy related nausea.
the role of periodontal diseases and stimulation of saliva secretion in the acute phase of ischemic stroke

Conditions: Periodontal Diseases; Saliva Altered; Stroke

Summary: methods: 100 consecutive patients with their first ever ischemic stroke were enrolled in the study. 56 randomly selected patients were subjected to stimulation of salivation, the remaining patients were not stimulated. the severity of the neurological condition was assessed using the nihss scale on days 1, 3 and 7 of stroke. the incidence of periodontal diseases was classified using the hall's scale in the 1st day of stroke. on days 1 and 7 of stroke, the concentration of il-1beta, mmp8, opg and rankl in the patients' saliva was assessed using the elisa technique. at the same time, the level of crp and the number of leukocytes in the peripheral blood were tested on days 1, 3 and 7 of the stroke, and the incidence of upper respiratory and urinary tract infections was assessed.

the course of an ischemic stroke varies by many factors. the influence of periodontal diseases and the stimulation of salivation on the course and difficulty of stroke remains unresolved. methods: 100 consecutive patients with their first ever ischemic stroke were enrolled in the study. 56 randomly selected patients were subjected to stimulation of salivation, the remaining patients were not stimulated. the severity of the neurological condition was assessed using the nihss scale on days 1, 3 and 7 of stroke. the incidence of periodontal diseases was classified using the hall's scale in the 1st day of stroke. on days 1 and 7 of stroke, the concentration of il-1beta, mmp8, opg and rankl in the patients' saliva was assessed using the elisa technique. at the same time, the level of crp and the number of leukocytes in the peripheral blood were tested on days 1, 3 and 7 of the stroke, and the incidence of upper respiratory and urinary tract infections was assessed.

Eligibility criteria:
inclusion criteria: * men and women, * at the age of 48-80, * first-ever stroke, * with symptoms from the anterior cerebral vascularity (basin of the internal carotid artery), * with a significant neurological deficit (minimum 3 points according to the nih scale) * capable of giving informed consent; exclusion criteria: * aphasia, disturbance of consciousness, mental disorders - making it impossible to express informed consent * surgery of the salivary glands - disrupting the secretion of saliva * diseases of the salivary glands that disrupt the secretion of saliva (diabetes, sjögren's syndrome, state after radiotherapy in the area of the salivary glands)
sexual health texting intervention to support adolescent females

Conditions: Teen Sexual Health

Summary: this study aims to use a text messaging intervention to prevent unintended teen pregnancy and transmission of sexually transmitted disease. the study will be informed by a formative qualitative phase (february 2014 - january 2015) which will include individual qualitative interviews and focus groups with teens to elucidate and explore the barriers to effective contraceptive use and sexually transmitted disease (std) prevention and to obtain feedback on the developed intervention. the second efficacy phase will randomize subjects to the texting intervention or to usual care.

adolescents, particularly those from disadvantaged backgrounds, are disproportionally affected by both unintended pregnancies and stds. while youth only represent a quarter of the sexually active population in the us, they account for almost half of all new stds and the rate of unintended pregnancies among sexually active teens is almost double the rate of all sexually active women. teen mothers experience higher rates of negative social outcomes including school dropout and children of teens are more likely to have low birth weight, lower academic achievement and more likely to perpetuate the cycle of teen pregnancy themselves. both unintended pregnancies and stds are much higher among racial/ethnic minority populations. contraceptive methods considered most effective for pregnancy prevention do not protect against stds and hiv transmission. dual protection methods include being on an effective and consistent form of contraception and having an effective std prevention method in place, preferably consistent condom use. non-penetrative sexual practices can be substituted. there are many barriers to providing sexual health education and services in the context of primary care visits. a recent study of pediatricians found that 61% of pediatricians reported discussing contraception, use of condoms and/or stds with patients at preventive care visits. most providers (76%), however, believed they did not have sufficient time to provide such counseling in the visit. the problems are even more acute in resource-limited safety net settings. therefore, a two-tiered approach may prove to be useful, where providers initially address reproductive health issues in the visit but where additional support outside the visit provides additional information, support, motivation and connection to services. an innovative intervention using texting technology may prove to be a cost effective method of providing support between visits.

Eligibility criteria:
inclusion criteria: * biologically female; * between 13 and 18 years of age; * not currently pregnant or trying to become pregnant; * have texting capability; and * able to read/write/speak in english. exclusion criteria: * not meeting inclusion criteria outlined above
antidepressant treatment of aids related depression.

Conditions: Depression

Summary: to test the effectiveness treating aids related depression with imipramine hydrochloride. depression syndromes are commonly associated with chronic, disabling, and fatal diseases. due to the relentless course of hiv infection, there is a certain reluctance to treat the associated depression. in other illness, it has been proven that treating the depression often results in improvement of overall health status. this is a placebo controlled trial. half of the patients are given imipramine hydrochloride every day for 6 weeks. assessment is done by self reports and the hamilton depression rating scale. prior to entry all patients are given a psychiatric evaluation. there is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

to test the effectiveness treating aids related depression with imipramine hydrochloride. depression syndromes are commonly associated with chronic, disabling, and fatal diseases. due to the relentless course of hiv infection, there is a certain reluctance to treat the associated depression. in other illness, it has been proven that treating the depression often results in improvement of overall health status. this is a placebo controlled trial. half of the patients are given imipramine hydrochloride every day for 6 weeks. assessment is done by self reports and the hamilton depression rating scale. prior to entry all patients are given a psychiatric evaluation. there is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Eligibility criteria:
inclusion criteria: * patient must be ambulatory and relatively good health. even if unable to work at least able to partially care care for self and not demented. * may have been alcoholic or drug abuser 6 months previous. * unspecified * cd4 unspecified. exclusion criteria: * non ambulatory patients or those requiring extensive help in self care are excluded. * non ambulatory patients or those requiring extensive help in self care are excluded. * current alcohol or drug abuse. * unspecified

Keywords: adult acquired immunodeficiency syndrome depression female human imipramine male middle age acquired immunodeficiency syndrome -- *complications depression -- *drug therapy depression -- etiology imipramine -- *therapeutic use
a prospective, longitudinal study of endothelial function in hiv/hcv coinfected subjects

Conditions: HIV; Hepatitis C

Summary: the ctsi-place study is a study for men and women with hiv/hepatitis c co-infection or hiv only. the study looks at the impact of having hepatitis c virus in addition to hiv on risk for cardiovascular disease. participants will undergo non-invasive assessment of cardiovascular disease risk through measurements of endothelial function and blood biomarkers at baseline and 1 year (or 4 weeks and 24 weeks after end of hcv treatment for those that undergo hcv treatment during study follow-up).


Eligibility criteria:
inclusion criteria 1. men and women ≥ 18 years 2. hepatitis c negative or chronic hepatitis c infection 3. chronic hiv infection 4. cd4+ t-cell count \> 200 cells/mm3 5. plasma hiv-1 rna \< 50 copies/ml 6. on continuous and stable art for at least 12 weeks 7. ability and willingness to provide written informed consent. exclusion criteria 1. known cardiovascular disease 2. diabetes requiring insulin therapy or hemoglobin a1c \> 8% 3. inability to conform to requirements for pat testing 4. decompensated liver disease 5. other known causes of significant liver disease 6. serious illness including acute liver-related disease and malignancy requiring systemic treatment or hospitalization within 12 weeks prior to study entry 7. presence of active or acute aids-defining opportunistic infections (ois) within 12 weeks prior to study entry 8. history of major organ transplantation with an existing functional graft and on immunosuppressive therapy 9. history of known vascular or autoimmune disease 10. pregnancy 11. hcv treatment (any approved or investigational agents) within 24 weeks prior to study entry 12. use of immune-based therapies or systemic corticosteroids within 12 weeks prior to study entry 13. advanced renal insufficiency as defined by glomerular filtration rate (gfr) \< 30 ml/min/1.73 m2 or treatment by dialysis

Keywords: endothelial function cardiovascular risk hiv hepatitis c metabolic disease inflammation
comparison efficacy of 14-day concomitant therapy:clarithromycin vs.levofloxacin in eradication of h.pylori

Conditions: Helicobacter Pylori Gastrointestinal Tract Infection

Summary: comparison efficacy of 14-day concomitant therapy between levofloxacin and clarithromycin on the eradication of helicobacter pylori in syrian population


Eligibility criteria:
inclusion criteria: -patients are aged greater than 18 years old who have h. pylori infection diagnosed by any of following three methods: i-positive rapid urease test (clotest). ii-histologic evidence of h. pylori by modified giemsa staining. iii-positive 13c-urea breath test. without prior eradication therapy and are willing to receive therapy. exclusion criteria: * children and teenagers aged less than 18 years. * previous eradication treatment for h. pylori. * patients who took any drug, which could influence the study results such as proton pump inhibitor, h2 blocker, mucosal protective agent and antibiotics. * history of gastrectomy. * gastric malignancy, including adenocarcinoma and lymphoma, * previous allergic reaction to antibiotics (amoxicillin, tinidazole , levofloxacin) and prompt pump inhibitors (es-omeprazole). * contraindication to treatment drugs. * pregnant or lactating women. * severe concurrent disease. liver cirrhosis. chronic kidney disease. * patients who cannot give informed consent by himself or herself.

Keywords: helicobacter pylori helicobacter infections proton pump inhibitors sequential therapy clarithromycin tinidazole
a phase 1/phase 2 study of polyvalent pneumococcal conjugate vaccine (v116) in adults (v116-001)

Conditions: Pneumonia, Pneumococcal

Summary: this phase 1 and phase 2 study will evaluate the safety, tolerability and immunogenicity of v116 when administered to adults. phase 1 has no formal hypothesis. the primary hypotheses for phase 2 are: v116 is noninferior to pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (opa) geometric mean titers (gmts) for the common serotypes at 30 days postvaccination and that the serotype-specific opa gmts for the unique serotypes in v116 at 30 days postvaccination are statistically significantly greater following vaccination with v116 than those following vaccination with pneumovax™23.


Eligibility criteria:
inclusion criteria * phase 1: * male or female, from 18 years to 49 years of age inclusive * phase 2: * male or female ≥50 years of age phase 1 and phase 2 * males: refrain from donating sperm, remain abstinent during study or agree to use condom * females: not pregnant. if a woman of childbearing potential, agree to use contraception or remain abstinent exclusion criteria * history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years of screening * known hypersensitivity to any component of the ppcv, or any diphtheria toxoid-containing vaccine * known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (hiv) infection, functional or anatomic asplenia, or history of autoimmune disease * coagulation disorder contraindicating im vaccination * recent febrile illness (defined as oral or tympanic temperature ≥100.4°f \[≥38.0°c\] or axillary or temporal temperature ≥99.4°f \[≥37.4°c\]) or received antibiotic therapy for any acute illness occurring within 72 hours of screening * known malignancy that is progressing or has required active treatment within 3 years.(note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ \[eg, breast carcinoma, cervical cancer in situ\] that have undergone potentially curative therapy are not excluded) * pregnant * received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study, outside of the protocol. * receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease * received a blood transfusion or blood products, including immunoglobulin, 6 months before study vaccination or is scheduled to receive a blood transfusion or blood product
pilot study of remote ischemic preconditioning in heart failure

Conditions: Heart Failure; Left Ventricular Dysfunction

Summary: the purpose of this study is to determine the effect of remote ischemic preconditioning on exercise capacity in patients with heart failure.


Eligibility criteria:
inclusion criteria: * lv ejection fraction \<40% * nyha functional class ii-iv * non ischemic cardiomyopathy * stable exclusion criteria: * recent cardiovascular hospitalization (within last 4 weeks) * ischemic cardiomyopathy * diabetes mellitus * peripheral neuropathy * ventricular assist device * contraindications to exercise stress testing

Keywords: exercise remote ischemic preconditioning heart failure left ventricular dysfunction